Core Insights - Purple Biotech has announced a collaboration with Converge Bio to enhance its tri-specific antibody platform using generative AI for oncology applications [1][3] - The collaboration aims to accelerate drug discovery timelines and improve the quality of therapeutic candidates targeting solid tumors [1][4] Company Overview - Purple Biotech is a clinical-stage company focused on developing next-generation immunotherapy platforms that maximize anti-cancer potency while minimizing toxicity [9] - The company's lead program, CAPTN-3, involves masked tri-specific antibodies that engage both T cells and NK cells, enhancing therapeutic efficacy [8][9] Collaboration Details - The partnership will leverage Converge Bio's AI platform, which integrates large-scale biological data with predictive modeling to optimize antibody candidates [3][5] - This collaboration is expected to expand Purple Biotech's pipeline with high-quality candidates while reducing development timelines [4][6] Technology and Innovation - The CAPTN-3 platform utilizes proprietary capping technology to confine immune activation to the tumor microenvironment, significantly improving the therapeutic window compared to traditional T-cell engagers [8][9] - The collaboration aims to develop novel T cell engagers that combine optimal functional properties with favorable physicochemical characteristics [3][4] Strategic Goals - The integration of AI into Purple Biotech's development strategy positions the company at the forefront of innovation in multi-specific antibody therapies [3][5] - The collaboration is seen as a strategic expansion to address additional high-value oncology targets and resistance mechanisms [6]

Core Viewpoint - Purple Biotech Ltd. has regained compliance with Nasdaq's minimum bid price requirement, allowing for continued listing on the Nasdaq Capital Market [2]. Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing a next-generation immunotherapy platform aimed at maximizing anti-cancer potency while minimizing toxicity [3]. - The company is advancing its lead program, CAPTN-3, which utilizes masked tri-specific antibodies to target tumors and engage T cells and NK cells [3]. - The lead candidate, IM1240, is progressing towards clinical trials, while the second candidate, IM1305, is in preclinical development [3]. - The pipeline includes additional clinical-stage assets such as CM24, a CEACAM1-blocking antibody, and NT219, a dual IRS1/2 and STAT3 inhibitor, both of which are in Phase 2 studies for various cancers [3].

Company Leadership Transition - Gil Efron will step down as CEO of Purple Biotech Ltd. effective August 2026 due to health considerations, but will continue to lead corporate development and remain on the Board of Directors [1][2] - The Board of Directors has initiated a search for a new CEO with experience in leading innovative biotechnology companies [2][3] - Efron has served in senior leadership roles for eight years, including as CFO and CEO, and has been instrumental in the company's strategic repositioning around the CAPTN-3 platform [3][4] CAPTN-3 Platform Overview - CAPTN-3 is Purple Biotech's lead program, featuring capped tri-specific antibodies that target tumor-associated antigens while engaging T cells and NK cells [4][5] - The proprietary capping technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers [4][5] - The lead candidates, IM1240 and IM1305, are in preclinical development, with IM1240 advancing toward clinical trials [5][6] Company Background - Purple Biotech Ltd. is a clinical-stage company focused on developing next-generation immunotherapy platforms aimed at maximizing anti-cancer potency while minimizing toxicity [5][6] - The company is headquartered in Rehovot, Israel, and is advancing its lead program, CAPTN-3, alongside additional clinical-stage assets [6]

Core Insights - The company is focusing on the development of tri-specific antibodies from the CAPTN-3 platform, specifically IM1240 and IM1305, targeting tumor-associated antigens 5T4 and TROP2 respectively [1][2] - Positive preclinical data indicates multi-arm anti-tumor activity for both IM1240 and IM1305, with an expanded therapeutic window and commercially viable yield achieved for IM1240 [1][3] - The company reported a total cash position of $9.5 million as of December 31, 2025, which is expected to provide operational runway into 2027 [1][13] Development Highlights - The CAPTN-3 platform has shown significant and sustained tumor regression across IM1240 and IM1305, with transcriptomic analysis supporting the inclusion of the NKG2A arm in designs [6][7] - IM1240 demonstrated improved tolerability in toxicology studies, with doses up to 300-fold higher than a non-capped comparator, and significantly reduced immune-related toxicity [6] - Manufacturing milestones for IM1240 have been achieved, positioning the program competitively for future development [5] Financial Performance - For the three months ended December 31, 2025, research and development expenses increased to $1.8 million from $0.5 million in the same period of 2024, primarily due to CAPTN-3 platform development activities [8] - General and administrative expenses rose to $1.1 million compared to $0.6 million in the same period of 2024, attributed to increased professional services fees [9] - The company recognized a $20.5 million impairment loss related to in-process research and development assets CM24 and NT219, reflecting a strategic focus on the CAPTN-3 platform [10][15] Loss and Cash Flow - The operating loss for the year ended December 31, 2025, was $27.5 million, an increase from $11 million in 2024, primarily due to the impairment expenses [16] - The net loss for the year was $26.4 million, or $54.9 loss per basic ADS, compared to a net loss of $7.2 million in 2024 [17] - Cash and cash equivalents at the end of 2025 were $8.7 million, up from $7.4 million at the end of 2024, indicating a net increase in cash flow [30]

Core Viewpoint - Purple Biotech Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to regain compliance with Nasdaq's minimum bid price requirement, effective March 2, 2026 [1][2]. Group 1: ADS Ratio Change - The ADS Ratio will change from 1 ADS representing 200 ordinary shares to 1 ADS representing 2,000 ordinary shares, effectively a one-for-ten reverse ADS split [1][2]. - Registered holders of certificated ADSs must surrender their ADSs for cancellation to receive new ADSs, while holders of uncertificated ADSs will have their ADSs automatically exchanged [2]. - The new CUSIP number assigned due to the ADS Ratio Change is 74638P307, and the ADSs will continue to trade under the symbol "PPBT" on Nasdaq [2]. Group 2: Impact on Trading - The ADS trading price is expected to increase proportionally as a result of the ADS Ratio Change, enhancing its suitability for trading on Nasdaq [4]. - There is no assurance that the ADS trading price post-change will be equal to or greater than ten times the price before the change [4]. Group 3: Company Overview - Purple Biotech is a clinical-stage oncology company focused on developing therapies to overcome tumor immune evasion and drug resistance [5]. - The lead program, CAPTN-3, involves capped tri-specific antibodies targeting tumors while engaging T cells and NK cells, with candidates IM1240 and IM1305 in various stages of development [5]. - The pipeline includes clinical-stage assets like CM24 and NT219, targeting specific cancer types with promising outcomes in clinical studies [5].

Core Insights - IM1240, a tri-specific antibody from Purple Biotech's CAPTN-3 platform, has shown improved safety in a toxicology study, allowing doses up to 300-fold higher than a non-capped comparator with significantly reduced immune-related toxicity [1][2][3] - The pharmacokinetic profile of IM1240 indicates increased systemic exposure and a prolonged circulating half-life, supporting its therapeutic potential [1][3] - Purple Biotech plans to submit for regulatory approval for first-in-human clinical trials in the second half of 2026 [1] Study Results - The toxicology study demonstrated that IM1240's proprietary capping technology significantly reduced immune-related toxicity, including minimal cytokine release, compared to a non-capped comparator [2][3] - Hematologic findings in the study aligned with expected pharmacodynamic effects on immune activation, showcasing a favorable safety and tolerability profile [3] - The capping design of IM1240 allowed for a significant reduction in immune-related effects, maintaining modest cytokine release even at high doses [3] Pharmacokinetics - IM1240 exhibited a favorable pharmacokinetic profile characterized by dose-dependent increases in systemic exposure, as indicated by AUC and Cmax [3] - The findings support the dose-exposure relationship and provide proof of concept for the capping design and albumin incorporation contributing to IM1240's favorable pharmacokinetic profile [3] CAPTN-3 Platform Overview - The CAPTN-3 platform consists of capped tri-specific antibodies that target tumor-associated antigens while engaging T cells and NK cells, significantly expanding the therapeutic window compared to conventional T-cell engagers [4][5] - IM1240 targets the 5T4 antigen, while another candidate, IM1305, targets TROP2 and is currently in preclinical development [4][5] Company Background - Purple Biotech Ltd. is a clinical-stage oncology company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [5] - The company's pipeline includes additional clinical-stage assets, such as CM24 and NT219, which are in various stages of clinical trials [5]

Core Insights - The CAPTN-3 platform by Purple Biotech demonstrates significant tumor regression through two tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens [1][2] - The NKG2A arm is crucial for enhancing the anti-cancer immune activity of IM1240, particularly in PD1-resistant patient-derived explants [1][3] Group 1: CAPTN-3 Platform and Antibodies - The CAPTN-3 platform combines T-cell engagement, NKG2A-mediated immune activation, and tumor-antigen targeting into a single tri-specific molecule, showing potential for a synergistic immune response [2][3] - IM1240 has shown strong anti-tumor activity in PD1-resistant models, indicating its effectiveness even in previously resistant tumors [4][6] - IM1305, targeting TROP2, demonstrates high-affinity binding and potent tumor cell killing across various cancer types, reinforcing the platform's versatility [9] Group 2: Preclinical Data and Findings - New preclinical data presented at the ESMO Immuno-Oncology Congress 2025 highlights the anti-tumor activity of IM1240 in models resistant to PD1 therapy [1][2] - Transcriptomic analysis of approximately 11,000 TCGA samples indicates a strong association between NKG2A expression and tumor expression of 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs [1][6] - IM1305 induced sustained tumor regression in humanized triple-negative breast cancer mouse models at low doses, demonstrating broad application potential [7]

Core Insights - Purple Biotech Ltd. is set to present new preclinical data from its CAPTN-3 platform at the ESMO-IO 2025 Annual Congress, highlighting its potential in treating resistant cancers [1][3]. Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance [5]. - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [5]. CAPTN-3 Platform - The CAPTN-3 platform can produce tri-specific antibodies that engage T cells and NK cells while binding to tumor-associated antigens, demonstrating strong synergy in preclinical studies [3]. - The platform's unique design allows for localized immune responses within the tumor microenvironment, potentially increasing the therapeutic window for patients [5]. Lead Program IM1240 - IM1240 is the first tri-specific antibody in development targeting the 5T4 antigen, which is associated with various solid tumors and poor clinical outcomes [5]. - New data from IM1240 will be showcased in multiple PD-1 resistant models at the upcoming congress [3]. Other Pipeline Products - CM24 is a humanized monoclonal antibody that blocks CEACAM1, a target for multiple cancer indications, and has shown improvement in a Phase 2 study for pancreatic ductal adenocarcinoma [5]. - NT219 is a dual inhibitor targeting IRS1/2 and STAT3, with demonstrated anti-tumor activity in combination with cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck [5]. Presentation Details - The presentation at the ESMO-IO 2025 Annual Congress will be led by Dr. Hadas Reuveni, focusing on the unique design of the CAPTN-3 platform [7].

Core Insights - Purple Biotech Ltd. has initiated the development of a second tri-specific antibody, IM1305, targeting TROP2, and achieved a manufacturing milestone for its first tri-specific antibody, IM1240, which targets 5T4 [1][4] - The company reported a cash position of $10.5 million as of September 30, 2025, with an expected cash runway into the first half of 2027, supporting the development of its CAPTN-3 technology platform [1][10] Financial Performance - Research and Development Expenses for the three months ended September 30, 2025, were $0.6 million, a decrease of 56.4% from $1.3 million in the same period of 2024, primarily due to reduced costs associated with the CM24 Phase 2 study [5] - General and Administrative Expenses remained consistent at $0.8 million for the three months ended September 30, 2025, compared to the same period in 2024 [6] - The Operating Loss for the three months ended September 30, 2025, was $1.4 million, a decrease of 35.8% from $2.1 million in the same period of 2024 [6] - The Net Loss for the three months ended September 30, 2025, was $1.3 million, or $0.29 per basic and diluted ADS, compared to a net loss of $0.7 million, or $0.39 per basic and diluted ADS, in the same period of 2024 [9] Clinical and Corporate Developments - The company plans to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND), and initiate a Phase 1 study for IM1240 in 2026 [2] - IM1240 has demonstrated tumor cell death in patient-derived, treatment-resistant head and neck biopsies, advancing toward first-in-human clinical trials [4] - The CM24 Phase 2 study will utilize identified biomarkers for patient selection in the upcoming Phase 2b study, which is subject to partnering [4] Patent and Intellectual Property - Purple Biotech received an intention to grant a European patent covering NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor resistance [3][5]

Group 1: Stock Price Movements - Globalink Investment Inc. experienced a significant surge, with its stock price jumping to $0.09, marking a 581.82% increase, driven by heightened investor interest possibly due to speculative activities or potential business combination news [1][6] - Cambium Networks Corporation saw its stock price rise to $2.66, a 331.65% increase, attributed to the integration of its Cambium ONE Network solution with Starlink satellite Internet services, enhancing its growth prospects [2][6] - Purple Biotech Ltd. witnessed its stock price increase to $0.93, up by 59.74%, driven by promising updates on its clinical trials and strategic partnerships, particularly regarding its tri-specific antibody IM1240 [3][6] - Ernexa Therapeutics Inc. saw its price increase to $1.97, a 57.85% rise, influenced by investor optimism towards its innovative therapies and a partnership with Cellipont Bioservices for clinical trials [4][6] - VSee Health, Inc. experienced a 49.52% increase in its stock price to $0.17, reflecting growing investor interest in the telehealth sector amid ongoing healthcare trends [5] Group 2: Market Trends and Investor Sentiment - The stock movements underscore the dynamic nature of the market, where company-specific developments, sector trends, and broader economic factors significantly impact stock prices [5] - Investors and analysts closely monitor such changes to gauge market sentiment and identify potential investment opportunities [5]